Sirolimus-eluting stents for treatment of coronary artery disease

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The sirolimus-eluting coronary stent is a device/drug combination product consisting of a coronary stent system and the drug, sirolimus, also known as rapamycin, impregnated in a polymer coating. The sirolimus-eluting stent is used for the minimally invasive treatment of coronary artery obstruction in patients with symptomatic coronary artery disease who require percutaneous coronary angioplasty and stenting. Sirolimus is an immunomodulatory drug which is released gradually into the arterial wall to suppress scar tissue formation within the stent and adjacent areas.

Final publication URL
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=11868

Indexing Status
Subject indexing assigned by CRD

MeSH
Coronary Artery Bypass; Coronary Artery Disease; Drug-Eluting Stents; Sirolimus

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

AccessionNumber
32011000914

Date abstract record published
15/06/2011